[1] Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013;93(3):1247-1288. DOI: 10.1152/physrev.00037.2012.
[2] Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274(1):330-353. DOI: 10.1111/imr.12499
[3] Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. DOI: 10.1038/nrdp.2016.45
[4] Fan YW, Jiang SW, Chen JM, Wang HQ, Liu D, Pan SM, et al. A pulmonary source of infection in patients with sepsis-associated acute kidney injury leads to a worse outcome and poor recovery of kidney function. World J Emerg Med. 2020;11(1):18-26. DOI: 10.5847/wjem.j.1920-8642.2020.01.003
[5] Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. DOI: 10.1038/s41572-019-0069-0
[6] Xiao Z, Wilson C, Robertson HL, Roberts DJ, Ball CG, Jenne CN, et al. Inflammatory mediators in intra-abdominal sepsis or injury - a scoping review. Crit Care. 2015;19:373. DOI: 10.1186/s13054-015-1093-4
[7] Bermejo-Martin JF, Martín-Fernandez M, López-Mestanza C, Duque P, Almansa R. Shared Features of Endothelial Dysfunction between Sepsis and Its Preceding Risk Factors (Aging and Chronic Disease). J Clin Med. 2018;7(11): 400. DOI: 10.3390/jcm7110400
[8] Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25-37. DOI: 10.1016/j.bbcan.2005.08.004
[9] Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G. Characterization of the secreted form of endothelial-cell-specific molecule1 by specific monoclonal antibodies. JVascRes. 2000;37(5):417-425. DOI: 10.1159/000025758
[10] Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu W, et al. Expression and distribution of endocan in human tissues. Biotechnic & histochemistry. 2012;87(3):172-178. DOI: 10.3109/10520295.2011.577754
[11] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. CritCare Med. 2001;29(7):1303–1310.DOI: 10.1097/00003246-200107000-00002
[12] Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndromes. Blood. 2003;101(10)3765–3777.
[13] Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. Biol Chem. 2001;276(8):48341–48349.DOI: 10.1074/jbc.M108395200
[14] Cox LA, van Eijk LT, Ramakers BPC, Dorresteijn M, Gerretsen J, Kox M, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015;43:322–326. DOI: 10.1097/SHK.0000000000000320
[15] Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620–630. DOI: 10.1002/jcp.24485
[16] Hsiao SY, Kung CT, Tsai NW, Su CM, Huang CC, Lai YR, et al. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clinica Chimica Acta. 2018;483: 275–280. DOI: 10.1016/j.cca.2018.05.007
[17] Mihajlovic DM, Lendak DF, Brkic SV, Draskovic BG, Mitic GP, Aleksandra S. Novakov Mikic, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvascular Research. 2014;93:92-97. DOI: 10.1016/j.mvr.2014.04.004
[18] Abdollahi A, Shoar S, Nayyeri F, Shariat M. Diagnostic Value of Simultaneous Measurement of Procalcitonin, Interleukin-6 and hs-CRP in Prediction of Early-Onset Neonatal Sepsis. Mediterr J Hematol Infect Dis. 2012;4(1):e2012028. DOI: 10.4084/mjhid.2012.028
[19] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock:2016. Intensive Care Med. 2017;43(3):304-377. DOI: 10.1007/s00134-017-4683-6
[20] Akavipat P, Thinkhamrop J, Thinkhamrop B, Sriraj W. Acute Physiology and Chronic Health Evaluation (APACHE) II Score - the Clinical Predictor in Neurosurgical Intensive Care Unit. Acta Clin Croat. 2019;58(1):50-56. DOI: 10.20471/acc.2019.58.01.07
[21] Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009;37(5):1649-1654. DOI: 10.1097/CCM.0b013e31819def97
[22] Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide trends of severe sepsis in the 21st century(2000-2007). Chest. 2011;140 (5):1223-1231. DOI: 10.1378/chest.11-0352
[23] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of Global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2015;193 (3) :259-272. DOI: 10.1164/rccm.201504-0781OC
[24] Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit. Care Med. 2006;34(2):532-537. DOI: 10.1097/01.CCM.0000198525.82124.74
[25] Palud A, Parmentier-Decrucq E, Pastre J, De Freitas Caires N, Lassalle P, Mathieu D. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine. 2015;73(2):213-218. DOI: 10.1016/j.cyto.2015.02.013
[26] De Freitas Caires N, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22(1):280. DOI: 10.1186/s13054-018-2222-7
[27] Lin QY, Lang PP, Zhang YL, Yang XL, Xia YL,Bai J, et al. Pharmacological blockage of ICAM-1 improves angiotensin II-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes. Am J Physiol Heart Circ Physiol. 2019;317(6):H1301‐H1311. DOI: 10.1152/ajpheart.00566.2019
[28] De Freitas Caires N, Legendre B, Parmentier E, Scherpereel A, Tsicopoulos A, Mathieu D et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013,78-79:45-51. DOI: 10.1016/j.jpba.2013.01.035
[29] Ioakeimidou A, Pagalou E, Kontogiorgi M, Antoniadou E, Kaziani K, Psaroulis K, et al. Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction. Eur J Clin Microbiol Infect Dis. 2017;36 (10): 1749-1756.DOI: 10.1007/s10096-017-2988-6